Please do not leave this page until complete. This can take a few moments.
Xtalic Corp. of Marlborough has raised $10 million in venture capital financing from Matrix Partners, North Bridge Venture Partners and an investment consortium led by James Wolfensohn, a former head of the Wor
Framingham-based GTC Biotherapeutics Inc. lost $6.1 million in the third quarter of 2008, down from $8.4 million for the same quarter last year.
Acton-based Seachange International announced this morning that it has secured its first customer through a new partnership with Argela, a company based in Turkey.
The Mathworks of Natick is acting as the lead sponsor of the International Genetically Engineered Machine 2008 student competition held at MIT in Cambridge.
Boston-Power Inc. has expanded its Westborough headquarters at 2200 West Park Drive by 12,042 square feet.
Clinton software developer Baesis Inc. has formed a partnership with the Massachusetts Attorney Title Group.
Cognex Corp. of Natick reported a third quarter profit of $11.3 million, a 50 percent increase from the $7.6 million reported for the same period a year ago.
ThinkEngine Networks Inc. of Marlborough posted a net loss of $624,000 for the third quarter on revenue of $1 million.
Neuroptix Corp. of Acton has successfully raised $18.5 million in its Series B funding round to move closer to clinical trials for its eye test that could be used to diagnose people with Alzheimer's disease.
10. Keywords Are Key Getting found online is all about choosing the proper keywords. If you don’t know what to choose, ask your customers what words they would use to find you. 9. Observe
The state’s Department of Revenue has issued a draft of the tax incentives in the $1 billion 10-year life sciences bill that was passed earlier this year.
With all the drama on Wall Street in recent weeks, the stocks of Central Massachusetts companies have been plummeting and bouncing around just like the rest of the market.
Boston Scientific Corp. of Natick announced that it has received approval from the U.S. Food and Drug Administration for a carotid artery stent.
Marlborough-based Sepracor Inc. said it has moved a step closer to marketing its insomnia drug Lunivia in the European Union.